Jackson Acquisition Company
RJAC
New York Stock Exchange10.39
USD
- -
- -
CIK
0001852495
CUSIP
46653C106
Return %
Stock
S&P500
1Y
5.38
18.21
3Y
7.11
64.38
5Y
7.11
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Richard Lee Jackson
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2655 Northwinds Parkway Alpharetta GA United States of America 30009
- IPO Date
- Jan 31, 2022
- CIK
- 0001852495
- Website
- jacksonacquisitions.com
- Similar Companies
- Business
- Jackson Acquisition Company (NYSE: RJAC) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting healthcare services and healthcare technology companies. The company seeks opportunities in risk-based providers and services; alternate site healthcare providers and services; home care and hospice; behavioral health; and sectors addressing the labor shortage in healthcare, prioritizing targets with industry attractiveness, strong management teams, durable business franchises with dependable cash flow, significant growth potential, clear value propositions, and benefits from access to public capital markets. Founded in 2021 and headquartered in Alpharetta, Georgia, Jackson Acquisition Company leverages the extensive healthcare expertise of its leadership team, including President and CEO Richard L. Jackson, founder and chairman of Jackson Healthcare; Chairman John Ellis (Jeb) Bush; and directors such as former U.S. Senator David A. Perdue Jr., former CMS Administrator Marilyn B. Tavenner, and Jackson Health System President and CEO Carlos A. Migoya. The company completed its initial public offering in December 2021, raising approximately $223 million through 22.25 million units at $10.00 each, underwritten by BofA Securities, with separate trading of Class A common stock (RJAC) and warrants (RJAC.WS) commencing in January 2022. In a significant development, Jackson Acquisition Company announced in May 2023 its decision to redeem all outstanding public shares effective June 13, 2023, after failing to complete an initial business combination within the required timeframe under its charter and determining not to extend the deadline via sponsor contribution; as of December 2025, its shares continue to trade around $10.39 with a market capitalization of approximately $289 million, while a successor entity, Jackson Acquisition Company II (NYSE: JACS), priced its IPO in December 2024 raising $200 million targeting similar healthcare opportunities.